Page last updated: 2024-10-28

hexamethonium and Stroke

hexamethonium has been researched along with Stroke in 1 studies

Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gulliford, M1
Charlton, J1
Bhattarai, N1
Rudisill, C1

Other Studies

1 other study available for hexamethonium and Stroke

ArticleYear
Social and material deprivation and the cost-effectiveness of an intervention to promote physical activity: cohort study and Markov model.
    Journal of public health (Oxford, England), 2014, Volume: 36, Issue:4

    Topics: Adult; Cardiovascular Diseases; Chronic Disease; Cohort Studies; Cost-Benefit Analysis; Cultural Dep

2014